Director/PDMR Shareholding

RNS Number : 3701O
Intl. Biotechnology Trust PLC
01 October 2019
 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)

The Company was notified today that the number of shares held by Dr Veronique Bouchet, a non-executive Director of the Company has increased by 733 shares to 8,233 due to share purchases in relation to dividend reinvestment. Following this, Dr Bouchet's aggregate holding represents 0.02% of the Company's issued share capital.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Veronique Bouchet

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

International Biotechnology Trust plc

b)

LEI

213800N1QUJ744P76D11

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of no par value

 

GB0004559349

b)

Nature of the transaction

Share purchases in relation to dividend reinvestment

c)

Price(s) and volume(s)

Date

Price(s)

Volume(s)

13/02/2017

583.10p

97

13/02/2017

583.10p

38

12/09/2017

632.00p

35

12/09/2017

632.00p

91

12/09/2018

674.50p

40

12/09/2018

674.50p

102

12/02/2019

622.94p

46

12/02/2019

622.94p

117

12/09/2019

618.62p

120

12/09/2019

620.00p

47

 

d)

Aggregated information

-

Aggregated volume


-

Price

 

733

 

626.37p

e)

Date of the transaction

Various (see section (c) for details)

f)

Place of the transaction

London Stock Exchange

 

Date of announcement: 1 OCTOBER 2019


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBDBDGDBGBGCB
Investor Meets Company
UK 100